Разрешен к применению с 1995 года.
Видео о
Купить в
COVID-19 
По алфавиту
- A
- B
- C
- D
- E
- F
- G
- H
- I
- J
- K
- L
- M
- N
- O
- P
- Q
- R
- S
- T
- V
- W
- X
- Y
- Z
- І
- А
- Б
- В
- Г
- Д
- Е
- Ж
- З
- И
- К
- Л
- М
- Н
- О
- П
- Р
- С
- Т
- У
- Ф
- Х
- Ц
- Ч
- Ш
- Щ
- Э
- Ю
- Я
- Весь список
Warning: mb_strpos(): Empty delimiter in /var/www/u1363561/data/www/biotech.spb.ru/wp-content/plugins/code-snippets/php/snippet-ops.php(581) : eval()’d code(4) : eval()’d code on line 13
A E Pedersen, J P Lauritsen
CD25 shedding by human natural occurring CD4+CD25+ regulatory T cells does not inhibit the action of IL-2Scand J Immunol. 2009 Jul;70(1):40-3.
A Fefer
Interleukin-2 in the treatment of hematologic malignanciesCancer J Sci Am. 1997 Dec;3 Suppl 1:S35-6.
A Fefer, M Benyunes, C Higuchi, A York, C Massumoto, C Lindgren, C D Buckner, J A Thompson
Interleukin-2 +/- lymphocytes as consolidative immunotherapy after autologous bone marrow transplantation for hematologic malignanciesActa Haematol. 1993;89 Suppl 1:2-7.
A Fefer, M C Benyunes, C Massumoto, C Higuchi, A York, C D Buckner, J A Thompson
Interleukin-2 therapy after autologous bone marrow transplantation for hematologic malignanciesSemin Oncol. 1993 Dec;20(6 Suppl 9):41-5.
A Fefer, N Robinson, M C Benyunes, W I Bensinger, O Press, J A Thompson, C Lindgren
Interleukin-2 therapy after bone marrow or stem cell transplantation for hematologic malignanciesCancer J Sci Am. 1997 Dec;3 Suppl 1:S48-53.
A G Niethammer, R Xiang, J M Ruehlmann, H N Lode, C S Dolman, S D Gillies, R A Reisfeld
Targeted interleukin 2 therapy enhances protective immunity induced by an autologous oral DNA vaccine against murine melanomaCancer Res. 2001 Aug 15;61(16):6178-84.
A Mazumder
Experimental evidence of interleukin-2 activity in bone marrow transplantationCancer J Sci Am. 1997 Dec;3 Suppl 1:S37-42.
A Nagler, A Ackerstein, R Or, E Naparstek, S Slavin
Immunotherapy with recombinant human interleukin-2 and recombinant interferon-alpha in lymphoma patients postautologous marrow or stem cell transplantationBlood. 1997 Jun 1;89(11):3951-9.
A Nagler, R Nagler, A Ackerstein, S Levi, Y Marmary
Major salivary gland dysfunction in patients with hematological malignancies receiving interleukin-2-based immunotherapy post-autologous blood stem cell transplantation (ABSCT)Bone Marrow Transplant. 1997 Oct;20(7):575-80.
A Ravaud, N Trufflandier, J M Ferrière, M Debled, J Palussière, L Cany, R Gaston, S Mathoulin-Pélissier, B N Bui
Subcutaneous interleukin-2, interferon alpha-2b and 5-fluorouracil in metastatic renal cell carcinoma as second-line treatment after failure of previous immunotherapy: a phase II trialBr J Cancer. 2003 Dec 15;89(12):2213-8.
A Ravaud, S Négrier, L Cany, Y Merrouche, M Le Guillou, J Y Blay, M Clavel, R Gaston, R Oskam, T Philip
Subcutaneous low-dose recombinant interleukin 2 and alpha-interferon in patients with metastatic renal cell carcinomaBr J Cancer. 1994 Jun;69(6):1111-4.
A Ravaud, S Négrier, L Cany, Y Merrouche, M Le Guillou, J Y Blay, M Clavel, R Gaston, R Oskam, T Philip
Subcutaneous low-dose recombinant interleukin 2 and alpha-interferon in patients with metastatic renal cell carcinomaBr J Cancer. 1994 Jun;69(6):1111-4.
A Toren, A Ackerstein, S Slavin, A Nagler
Role of interleukin-2 in human hematological malignanciesMed Oncol. 1995 Sep;12(3):177-86.
Abbas A.K., Trotta E., Simeonov D.R., Marson A., Bluestone J.A. 
PDF
Интерлейкин-2: механизмы регуляции и перспективы терапии.
Science Immunology. — 2018. — Vol. 3. — Issue 25. — Eaat 1482.
Abbas A.K., Trotta E., Simeonov D.R., Marson A., Bluestone J.A. PDF
Revisiting IL-2: Biology and therapeutic prospects.
Science Immunology. — 2018. — Vol. 3. — Issue 25. — Eaat 1482.
Abdulwahab Ali Gabeen, Fatma Farag Abdel-Hamid, Motawa Eisa El-Houseini, Shadia Abdel-Hamid Fathy
Potential immunotherapeutic role of interleukin-2 and interleukin-12 combination in patients with hepatocellular carcinomaJ Hepatocell Carcinoma. 2014 Jun 9;1:55-63.
Acién P, Velasco I, Acién M, Quereda F.
Treatment of endometriosis with transvaginal ultrasound-guided drainage and recombinant interleukin-2 left in the cysts: a third clinical trial.Gynecol Obstet Invest. 2010;69(3):203-11.
Acién P., Quereda FJ, Gómez-Torres MJ, Bermejo R, Gutierrez M.
GnRH analogues, transvaginal ultrasound-guided drainage and intracystic injection of recombinant interleukin-2 in the treatment of endometriosis.Gynecol Obstet Invest. 2003;55(2):96-104.
Adabi E, Saebi F, Moradi Hasan-Abad A, Teimoori-Toolabi L, Kardar GA.
Evaluation of an Albumin-Binding Domain Protein Fused to Recombinant Human IL-2 and Its Effects on the Bioactivity and Serum Half-Life of the Cytokine.Iran Biomed J. 2017 Mar;21(2):77-83. Epub 2016 Nov 2.
Alain Ravaud, Rémy Delva, Fréderic Gomez, Christine Chevreau, Jean-Yves Douillard, Jean Peny, Bruno Coudert, Sylvie Négrier, Groupe Français d’Immunothérapie
Subcutaneous interleukin-2 and interferon alpha in the treatment of patients with metastatic renal cell carcinoma-Less efficacy compared with intravenous interleukin-2 and interferon alpha. Results of a multicenter Phase II trial from the Groupe FrançaisCancer. 2002 Dec 1;95(11):2324-30.
Alana MacDonald, T-C Wu, Chien-Fu Hung
Interleukin 2-Based Fusion Proteins for the Treatment of CancerJ Immunol Res. 2021 Nov 8;2021:7855808.
Alba Grifoni, Daniela Weiskopf, Sydney I. Ramirez et al. PDF 
ZIP
Cell. 2020 Jun 25;181(7):1489-1501.e15. doi: 10.1016/j.cell.2020.05.015. Epub 2020 May 20.
Amr Mohamed El-Sabbagh, Samah Sabry El-Kazzaz, Ghada El-Saeed Mashaly, Wael
Alkhiary, Tarek Fouad Sheta PDF
Journal of Clinical Immunology and Immunopathology Research. Vol. 7(1), pp. 1-6, July 2016.
Ana Luisa Perdigoto, imageLucienne Chatenoud, imageJeffrey A. Bluestone, Kevan C. Herold.
Inducing and Administering Tregs to Treat Human Disease.Front. Immunol. — 2016. — 22 January . Sec.Vaccines and Molecular Therapeutics. https://doi.org/10.3389/fimmu.2015.00654.
Arnon Nagler, Raanan Berger, Aliza Ackerstein, Jaroslaw A Czyz, Jose Luis Diez-Martin, Elizabeth Naparstek, Reuven Or, Shlomit Gan, Avichai Shimoni, Shimon Slavin
A randomized controlled multicenter study comparing recombinant interleukin 2 (rIL-2) in conjunction with recombinant interferon alpha (IFN-alpha) versus no immunotherapy for patients with malignant lymphoma postautologous stem cell transplantationJ Immunother. 2010 Apr;33(3):326-33.
Asher Mullard.
Restoring IL-2 to its cancer immunotherapy glory.Nature reviews. DRug DISCoveRy. — 2021. — V. 20, march, p. 163-165.
Ashitkova N.V., Soldatova I.G, Degtyareva M.V., Volodin N.N.
Diagnostic and prognostic role of lymphopenia in critically ill newborns in neonatal intensive care unit (NICU).
The Journal of maternal-fetal & neonatal medicine. 2010. Vol. 23. Suppl. 1. P. 395.
Asim Amin, Richard L. White
High-Dose Interleukin-2: Is It Still Indicated for Melanoma and RCC in an Era of Targeted Therapies?Oncology (Williston Park). 2013 Jul;27(7):680-91.
Atzpodien J, Körfer A, Evers P et al.
Low-dose subcutaneous recombinant interleukin-2 in advanced human malignancy: a phase II outpatient study.Mol Biother. 1990 Mar;2(1):18-26. PMID: 2334534.
Azkur AK, Akdis M, Azkur D et al.
Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19.Allergy. 2020 Jul;75(7):1564-1581. doi: 10.1111/all.14364. PMID: 32396996; PMCID: PMC7272948.
В соответствии с п. 1 ст. 64 Федерального закона от 12.04.2010 № 61-ФЗ "Об обращении лекарственных средств" лекарственные препараты, находящиеся в обращении на территории Российской Федерации, подлежат мониторингу безопасности в целях выявления возможных негативных последствий их применения, предупреждения пациентов и их защиты от применения таких препаратов.